The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.
复制标题
DOI：
10.1186/s12967-022-03384-w
复制
发表时间：
2022-04-21
影响因子：
7.4
通讯作者：
Hwu, Patrick
中科院分区：
文献类型：
--
作者：
Ascierto, Paolo A.;Butterfield, Lisa H.;Finn, Olivera J.;Futreal, Andrew;Hamid, Omid;LaVallee, Theresa;Postow, Michael A.;Puzanov, Igor;Sosman, Jeffrey;Fox, Bernard A.;Hwu, Patrick
关键词：
作为2021年免疫治疗桥虚拟大会（1 - 2月1日至2日，意大利那不勒斯）的一部分，大辩论会议的特色是专家们被分配反对当今免疫治疗中四个重要问题的反对意见。第一个主题是溶瘤病毒或其他特异性免疫调节剂是否是更有希望的病灶内治疗方法。第二个是早期替代终点，如反应率或无进展生存期，是否与长期总生存期相关。第三，讨论了疫苗是否可以将冷肿瘤转化为热肿瘤，最后，比较了广泛与深入的分析分析方法，以深入了解免疫肿瘤学的发展。与以往的桥梁大会一样，演讲者是由会议主席邀请的，辩论期间采取的立场可能没有反映他们各自的个人观点。此外，本文中总结的观点基于现有证据，但可能反映了对这些数据的个人解释，临床经验和演讲者的主观意见。
As part of the 2021 Immunotherapy Bridge virtual congress (December 1–2, Naples, Italy), the Great Debate sessions featured experts who were assigned counter opposing views on four important questions in immunotherapy today. The first topic was whether oncolytic viruses or other specific immunomodulators were the more promising approach for intralesional therapy. The second was whether early surrogate endpoints, such as response rate or progression-free survival, correlate with long-term overall survival was considered. Thirdly, whether vaccines can transform cold into hot tumors was discussed and, finally, broad versus deep analytic profiling approaches to gain insights into immune-oncology development were compared. As with previous Bridge congresses, presenters were invited by the meeting Chairs and positions taken during the debates may not have reflected their respective personal view. In addition, the views summarised in this article are based on available evidence but may reflect personal interpretation of these data, clinical experience and subjective opinion of the speaker.
登录
查看更多内容
影响因子：
8.4
作者：
Hamid, Omid;Robert, Caroline;Daud, Adil;Carlino, Matteo S.;Mitchell, Tara C.;Hersey, Peter;Schachter, Jacob;V. Long, Georgina;Hodi, F. Stephen;Wolchok, Jedd D.;Arance, Ana;Grob, Jean Jacques;Joshua, Anthony M.;Weber, Jeffrey S.;Mortier, Laurent;Jensen, Erin;Diede, Scott J.;Moreno, Blanca Homet;Ribas, Antoni
通讯作者：
Ribas, Antoni
影响因子：
30.8
作者：
Miao D;Margolis CA;Vokes NI;Liu D;Taylor-Weiner A;Wankowicz SM;Adeegbe D;Keliher D;Schilling B;Tracy A;Manos M;Chau NG;Hanna GJ;Polak P;Rodig SJ;Signoretti S;Sholl LM;Engelman JA;Getz G;Jänne PA;Haddad RI;Choueiri TK;Barbie DA;Haq R;Awad MM;Schadendorf D;Hodi FS;Bellmunt J;Wong KK;Hammerman P;Van Allen EM
通讯作者：
Van Allen EM
影响因子：
51.1
作者：
da Silva, Ines Pires;Ahmed, Tasnia;Long, Georgina V.
通讯作者：
Long, Georgina V.
影响因子：
10.1
作者：
Maurer DM;Adamik J;Santos PM;Shi J;Shurin MR;Kirkwood JM;Storkus WJ;Butterfield LH
通讯作者：
Butterfield LH
用ipilimumab的tilsotolimod驱动抗PD-1难治性黑色素瘤中的肿瘤反应。
影响因子：
28.2
作者：
Haymaker C;Johnson DH;Murthy R;Bentebibel SE;Uemura MI;Hudgens CW;Safa H;James M;Andtbacka RHI;Johnson DB;Shaheen M;Davies MA;Rahimian S;Chunduru SK;Milton DR;Tetzlaff MT;Overwijk WW;Hwu P;Gabrail N;Agrawal S;Doolittle G;Puzanov I;Markowitz J;Bernatchez C;Diab A
通讯作者：
Diab A